Page 26 - 《中国药房》2023年20期
P. 26
Committee. 2019 China guideline for diagnosis and treat‐ [64] SIVAPALAN P，INGEBRIGTSEN T S，RASMUSSEN D
ment of infection-induced multiple organ dysfunction syn‐ B，et al. COPD exacerbations：the impact of long versus
drome in the elderly[J]. Chin J Mult Organ Dis Elder， short courses of oral corticosteroids on mortality and pneu‐
2019，18（11）：801-838. monia：nationwide data on 67 000 patients with COPD fol‐
[54] SHANE A L，MODY R K，CRUMP J A，et al. 2017 Infec‐ lowed for 12 months[J]. BMJ Open Respir Res，2019，6
tious Diseases Society of America clinical practice guide‐ （1）：e000407.
lines for the diagnosis and management of infectious diar‐ [65] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国
rhea[J]. Clin Infect Dis，2017，65（12）：1963-1973. 医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.
[55] MCDONALD L C，GERDING D N，JOHNSON S，et al. 慢性阻塞性肺疾病诊治指南：2021年修订版[J]. 中华结
Clinical practice guidelines for clostridium difficile infec‐ 核和呼吸杂志，2021，44（3）：170-205.
tion in adults and children：2017 update by the Infectious Chronic Obstructive Pulmonary Disease Group of Chinese
Diseases Society of America（IDSA）and Society for Thoracic Society，Chronic Obstructive Pulmonary Disease
Healthcare Epidemiology of America（SHEA）[J]. Clin In‐ Committee of Chinese Association of Chest Physician.
fect Dis，2018，66（7）：987-994. Guidelines for the diagnosis and management of chronic
[56] WHO. WHO consolidated guidelines on tuberculosis. obstructive pulmonary disease：revised version 2021[J].
Module 4：treatment-drug-resistant tuberculosis treatment， Chin J Tuberc Respir Dis，2021，44（3）：170-205.
2022 update[EB/OL].（2022-12-15）[2023-04-05]. https：// [66] RAMAKRISHNAN S，NICOLAU D V Jr，LANGFORD
www.who.int/publications/i/item/9789240063129. B，et al. Inhaled budesonide in the treatment of early
COVID-19（STOIC）：a phase 2，open-label，randomised
[57] NUNN A J，PHILLIPS P P J，MEREDITH S K，et al. A
controlled trial[J]. Lancet Respir Med，2021，9（7）：
trial of a shorter regimen for rifampin-resistant tuberculo‐
763-772.
sis[J]. N Engl J Med，2019，380（13）：1201-1213.
[67] REIS G，DOS SANTOS MOREIRA SILVA E A，
[58] GAFTER-GVILI A，FRASER A，PAUL M，et al. Meta-
MEDEIROS SILVA D C，et al. Oral fluvoxamine with in‐
analysis：antibiotic prophylaxis reduces mortality in neu‐
haled budesonide for treatment of early-onset COVID-19：
tropenic patients[J]. Ann Intern Med，2005，142（12 Pt 1）：
a randomized platform trial[J]. Ann Intern Med，2023，176
979-995.
（5）：667-675.
[59] KLASTERSKY J，NAUROIS J D，ROLSTON K，et al.
[68] 国家卫生健康委员会办公厅，国家中医药管理局综合
Management of febrile neutropaenia：ESMO clinical prac‐
司. 关于印发新型冠状病毒感染诊疗方案（试行第十版）
tice guidelines[J]. Ann Oncol，2016，27（Suppl 5）：v111-
的通知[EB/OL].（2023-01-05）[2023-04-05].http：//www.
v118.
nhc.gov.cn/ylyjs/pqt/2023-01/32de5b2ff9bf4eaa88e75bdf7
[60] KAHRAMANOĞLU AKSOY E， PIRINÇCI SAPMAZ
223a65a.shtml.
F， GÖKTAŞ Z，et al. Comparison of Helicobacter pylori
General Office of the National Health Commission of
eradication rates of 2-week levofloxacin-containing triple
China，General Department of National Adiministration of
therapy， levofloxacin-containing bismuth quadruple
Traditional Chinese Medicine. Diagnosis and treatment
therapy，and standard bismuth quadruple therapy as a first-
plan for novel coronavirus infection：10th edition on trial
line regimen[J]. Med Princ Pract，2017，26（6）：523-529. [EB/OL]. （2023-01-05）[2023-04-05]. http：//www.nhc.gov.
[61] DAVIES L，ANGUS R M，CALVERLEY P M. Oral corti‐ cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.
costeroids in patients admitted to hospital with exacerba‐ shtml.
tions of chronic obstructive pulmonary disease：a prospec‐ [69] YU L M，BAFADHEL M，DORWARD J，et al. Inhaled
tive randomised controlled trial[J]. Lancet，1999，354 budesonide for COVID-19 in people at high risk of com‐
（9177）：456-460. plications in the community in the UK（PRINCIPLE）：a
[62] NIEWOEHNER D E，ERBLAND M L，DEUPREE R H， randomised，controlled，open-label，adaptive platform trial
et al. Effect of systemic glucocorticoids on exacerbations [J]. Lancet，2021，398（10303）：843-855.
of chronic obstructive pulmonary disease. Department of [70] CAI C，HE M Z，ZHONG S Q，et al. Add-on montelukast
Veterans Affairs Cooperative Study Group[J]. N Engl J vs double-dose budesonide in nonasthmatic eosinophilic
Med，1999，340（25）：1941-1947. bronchitis：a pilot study[J]. Respir Med，2012，106（10）：
[63] DING Z，LI X，LU Y，et al. A randomized，controlled mul‐ 1369-1375.
ticentric study of inhaled budesonide and intravenous [71] BAO W P，LIU P，QIU Z M，et al. Efficacy of add-on
methylprednisolone in the treatment on acute exacerbation montelukast in nonasthmatic eosinophilic bronchitis：the
of chronic obstructive pulmonary disease[J]. Respir Med， additive effect on airway inflammation，cough and life
2016，121：39-47. quality[J]. Chin Med J，2015，128（1）：39-45.
· 2452 · China Pharmacy 2023 Vol. 34 No. 20 中国药房 2023年第34卷第20期
